ClinicalTrials.gg

Program

coramitug

A development code. Also written as “NNC6019-0001”.

Its studies are led by Novo Nordisk.

Furthest: phase 3, since Sep 23, 20253 company-led studies, 2 open or runningNext primary completion: Feb 29, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk32 open or runningphase 3since Sep 23, 2025Jun 28, 2022Feb 29, 2028phase 2 · NCT06260709
  • Named in Novo Nordisk’s own pipeline as Coramitug in ATTR-CM, phase 3, as of Nov 5, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 28, 2022First study: phase 2 study in Transthyretin Amyloid Cardiomyopathy (ATTR CM)First studyNCT05442047 · 105 enrolled · United States, Canada, Czechia and more
  2. Feb 7, 2024Phase 2 study in Transthyretin Amyloid Cardiomyopathy (ATTR CM)NCT06260709 · 88 enrolled · United States, Canada, Czechia and more
  3. Sep 23, 2025Phase 3 study in Transthyretin Amyloid Cardiomyopathy (ATTR CM)NCT07207811 · 1,280 planned · United States, Argentina, Australia and more

Ahead

  1. Feb 29, 2028Primary completion: phase 2 study in Transthyretin Amyloid Cardiomyopathy (ATTR CM)NCT06260709
  2. Jun 29, 2029Primary completion: phase 3 study in Transthyretin Amyloid Cardiomyopathy (ATTR CM)NCT07207811

TargetBeta

“Coramitug is a monoclonal antibody that potentially binds to the accumulations of the transthyretin protein and promotes its removal from the heart.”study summary, read by Claude · the study

Other programs on TTR

ProgramCompanyFurthest phaseStudies
tafamidisrulePfizerphase 429
acoramidisruleBridgeBiophase 415
coramitugNovo Nordiskphase 12

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07207811Transthyretin Amyloid Cardiomyopathy (ATTR CM) · United States, Argentina, Australia and more3RecruitingJun 29, 20291,280
NCT06260709Transthyretin Amyloid Cardiomyopathy (ATTR CM) · United States, Canada, Czechia and more2Active, not recruitingFeb 29, 202888
NCT05442047Transthyretin Amyloid Cardiomyopathy (ATTR CM) · United States, Canada, Czechia and more2CompletedFeb 17, 2025105

How it is read

Names in the registry

  • “NNC6019-0001”, 3 entries

Codes read as this program: NNC60190001.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.